Joel provides insight to various oncology and CNS therapeutics-focused clientele (biotechnology/pharmaceutical) on fundamental issues in drug development and partnering, based on a comprehensive analysis of the key scientific, clinical, regulatory, and commercial strategy questions relevant to the client’s particular situation.
In previous industry roles, Joel was instrumental in the scouting and evaluation of licensing and partnering opportunities for various oncology assets. Prior to his BD&L activities, Joel spent 10 years focused on the discovery and characterization of bioactive compounds for cancer and infectious disease research at several leading academic institutions. His work has resulted in numerous grants, fellowships, patent filings, and peer-reviewed publications. He received his BA with honors from Cornell University, a PhD in Organic Chemistry from UCSD/Scripps, and was a NIH Postdoctoral Fellow at The Rockefeller University.
He is a member of numerous professional societies, including the American Academy of Neurology (AAN), American Neurological Association (ANA), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the American Association for Cancer Research (AACR), and the American Association of Neurology (AAN).